The global in-vitro diagnostics (IVD) market size is likely to be valued at US$82.1 billion in 2026 and is expected to reach US$125.2 billion by 2033, growing at a CAGR of 6.2% during the forecast period from 2026 to 2033, driven by rising chronic disease burden, increased demand for early disease detection, and rapid adoption of molecular diagnostics and point-of-care testing.

According to the World Health Organization (WHO, 2025), non-communicable diseases and infectious disease surveillance needs are significantly increasing diagnostic testing volumes worldwide, strengthening IVD demand. The U.S. Centers for Disease Control and Prevention (CDC, 2024) highlights growing utilization of advanced laboratory testing for cancer screening, infectious disease monitoring, and antimicrobial resistance tracking.

Driver - Rising Prevalence of Chronic and Infectious Diseases

The increasing burden of diabetes, cardiovascular disorders, cancer, and respiratory diseases is significantly expanding the demand for routine and advanced diagnostic testing. The World Health Organization (WHO) estimates that non-communicable diseases (NCDs) account for 74% of global deaths annually, with diabetes, cardiovascular disease, and cancer representing the leading contributors. Infectious diseases such as influenza, tuberculosis, HIV, and emerging viral outbreaks continue to require large-scale screening and rapid testing solutions.

This growing patient pool is directly increasing the utilization of immunoassay, molecular diagnostics, and clinical chemistry platforms across hospitals and diagnostic laboratories. Healthcare systems are increasingly focusing on early disease detection and preventive screening programs, which strengthens diagnostic demand.

Governments and health organizations are expanding national screening initiatives to reduce long-term treatment costs and improve patient outcomes. The integration of advanced diagnostic technologies enables faster and more accurate disease identification, supporting timely clinical decision-making. Rising awareness among patients regarding health monitoring and regular testing also contributes to market expansion.

Restraint - Healthcare Workforce Shortages and Laboratory Capacity Constraints

The industry depends heavily on skilled laboratory professionals, pathologists, and technicians. Many regions, especially developing economies, face a shortage of trained diagnostic personnel, which limits efficient test processing and delays result reporting. High workload pressure on existing staff increases the risk of operational inefficiencies and diagnostic errors. This shortage restricts the optimal utilization of advanced diagnostic instruments and automated platforms.

Laboratory capacity constraints challenge market expansion, particularly in high-demand healthcare systems. Many diagnostic facilities operate with limited infrastructure, outdated equipment, and insufficient automation, which restricts scalability during disease outbreaks or peak testing demand. Inadequate investment in laboratory modernization and uneven distribution of diagnostic facilities across rural and urban areas exacerbate accessibility issues.

Opportunity - Liquid Biopsy and Oncology Diagnostics

Liquid biopsy enables the detection of circulating tumor DNA and biomarkers through simple blood samples, eliminating the need for invasive tissue biopsies. This approach supports early cancer detection, real-time monitoring of treatment response, and identification of genetic mutations. Increasing adoption of personalized medicine and companion diagnostics is accelerating the integration of advanced molecular technologies in oncology workflows across clinical laboratories and specialized cancer centers.

Continuous innovation in next-generation sequencing and molecular diagnostic platforms is expanding the clinical utility of oncology testing. Pharmaceutical companies are increasingly collaborating with diagnostic firms to develop targeted therapies supported by biomarker-based testing. Liquid biopsy enables the detection of circulating tumor DNA (ctDNA), exosomes, and other biomarkers from blood samples, reducing reliance on invasive tissue biopsies. It supports early cancer detection, recurrence monitoring, and therapy selection.

Guardant Health’s Guardant360 CDx is widely used in advanced oncology settings for genomic profiling and treatment guidance in lung and colorectal cancers. The U.S. Food and Drug Administration (FDA, 2024-2025 updates) continues to approve companion diagnostics linked to targeted cancer therapies, strengthening integration of diagnostics and pharmaceuticals. Next-generation sequencing (NGS) adoption is expanding rapidly in clinical laboratories, enabling high-precision mutation analysis and personalized treatment planning.

Product Type Insights

Reagents are expected to lead accounting for 69% of revenue in 2026. Their recurring nature and continuous demand in routine laboratory testing. Every diagnostic test, whether in clinical chemistry, immunoassay, or molecular workflows, relies heavily on reagents, making them an essential consumable across hospitals and diagnostic laboratories. A notable example includes Roche Diagnostics, which generates a significant portion of its diagnostics revenue from reagent kits used in immunoassay and molecular testing platforms such as cobas systems.

Instruments are likely to represent the fastest-growing segment, supported by increasing automation, digitalization of laboratories, and rising demand for high-throughput diagnostic systems. Laboratories are shifting from manual processes to fully automated analyzers to improve accuracy, speed, and efficiency in test reporting. For instance, Siemens Healthineers ADVIA and Atellica diagnostic systems are widely adopted in modern laboratories to streamline workflows.

Technology Insights

Immunoassay is projected to lead the market, capturing around 35% of the revenue share in 2026, supported by its broad clinical applicability, high sensitivity, and cost-effectiveness. It is widely used for hormone testing, infectious disease screening, and chronic disease monitoring, making it a core diagnostic method in hospitals and laboratories. For example, Abbott ARCHITECT immunoassay systems are extensively used in clinical laboratories for detecting infectious diseases and cardiac markers.

Molecular diagnostics are likely to be the fastest-growing technology type due to advancements in PCR, next-generation sequencing (NGS), and increasing demand for precision medicine. A notable example includes QIAGEN’s QIAstat-Dx and PCR-based platforms, which are widely used for rapid pathogen identification and genetic analysis in hospitals and research laboratories.

Application Insights

Infectious diseases are expected to lead the in-vitro diagnostics (IVD) market, accounting for 50% share in 2026, supported by Continuous demand for disease screening, outbreak management, and routine diagnostic testing. Conditions such as influenza, tuberculosis, HIV, and respiratory infections require frequent and large-scale testing, driving sustained utilization of diagnostic platforms. For example, bioMérieux’s VIDAS and FilmArray systems are widely used in hospitals and laboratories for rapid detection of infectious pathogens.

Diabetes is likely to represent the fastest-growing segment, supported by the increasing prevalence of lifestyle-related disorders, obesity, and aging populations. Continuous glucose monitoring and HbA1c testing are becoming essential for long-term disease management and preventive healthcare strategies. For instance, Abbott’s FreeStyle Libre system enables continuous glucose monitoring for diabetic patients and improves disease management.

North America In-vitro Diagnostics (IVD) Market Trends

North America is anticipated to be the leading region, accounting for a market share of 44% in 2026, due to advanced healthcare infrastructure, high adoption of molecular diagnostics, and strong regulatory support for innovation. The region is witnessing rapid expansion in point-of-care testing, AI-enabled laboratory automation, and precision medicine-based diagnostics. A notable example includes Abbott Laboratories, which continues to expand its molecular diagnostics and rapid testing portfolio.

U.S. In-vitro Diagnostics (IVD) Market Trends

The U.S dominates the regional market, driven by strong FDA-approved innovation pipelines, widespread adoption of genomic testing, and increasing use of companion diagnostics in oncology. Recent growth is driven by rising cancer screening programs and the expansion of at-home diagnostic testing kits. The U.S. also benefits from strong reimbursement frameworks supporting advanced diagnostic procedures.

Canada In-vitro Diagnostics (IVD) Market Trends

Canada is a significant market for in-vitro diagnostics (IVD) through government-backed healthcare digitization programs and increased investment in centralized laboratory networks. Canada is also expanding infectious disease surveillance systems and improving access to molecular diagnostics in urban and remote healthcare facilities, strengthening overall diagnostic penetration.

Europe In-vitro Diagnostics (IVD) Market Trends

Europe is likely to be a significant market for in-vitro diagnostics (IVD) in 2026, due to strong regulatory frameworks, rising chronic disease burden, and increasing adoption of automated laboratory systems. The region is experiencing rapid growth in molecular diagnostics, cancer screening programs, and personalized medicine initiatives. For instance, Siemens Healthineers, which is advancing integrated diagnostic platforms and laboratory automation solutions.

U.K. In-vitro Diagnostics (IVD) Market Trends

The U.K. is a significant market for in-vitro diagnostics (IVD), supported by NHS-led screening programs, increasing adoption of AI-based diagnostics, and expansion of genomic medicine initiatives such as the Genomic Medicine Service. The UK is also investing heavily in early cancer detection programs and digital health transformation, improving access to advanced diagnostic technologies across public healthcare systems.

Germany In-vitro Diagnostics (IVD) Market Trends

Germany dominates the regional market due to its advanced healthcare infrastructure and strong adoption of digital pathology and laboratory automation. The country is focusing on precision diagnostics and expanding molecular testing capacity for oncology and infectious diseases. Government support for research and development is strengthening diagnostic innovation.

Asia Pacific In-vitro Diagnostics (IVD) Market Trends

The Asia Pacific region is likely to be the fastest-growing region in the in-vitro diagnostics (IVD) market in 2026. It's rising healthcare expenditure, expanding diagnostic infrastructure, and increasing disease burden across emerging economies. The region is witnessing strong adoption of point-of-care testing, molecular diagnostics, and automated laboratory systems. For example, F. Hoffmann-La Roche Ltd, which is expanding its diagnostics footprint in Asia through advanced PCR-based systems and high-throughput laboratory solutions, particularly in infectious disease and oncology testing across developing healthcare systems.

China In-vitro Diagnostics (IVD) Market Trends

China dominates the regional market, supported by a large patient population, strong government healthcare reforms, and rapid expansion of domestic diagnostic manufacturing. The country is investing heavily in precision medicine, cancer screening programs, and AI-enabled diagnostic platforms. China’s push for self-reliant medical technology production is also increasing local innovation.

India In-vitro Diagnostics (IVD) Market Trends

India is a significant market for in-vitro diagnostics (IVD). Due to the increasing prevalence of chronic diseases, rising awareness of preventive healthcare, and expansion of diagnostic chains in both urban and semi-urban areas. Government initiatives such as digital health infrastructure development and expanding insurance coverage are improving access to advanced IVD testing, significantly strengthening market penetration.

The global in-vitro diagnostics (IVD) market exhibits a moderately fragmented structure, driven by increasing demand for advanced molecular diagnostics, point-of-care testing, and AI-enabled laboratory automation. Large multinational companies are strengthening their portfolios through continuous innovation in immunoassay, clinical chemistry, and genomics-based platforms, while also expanding through mergers and acquisitions to enhance technological capabilities.

With key leaders including Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher (Cepheid & Beckman Coulter), bioMérieux, Thermo Fisher Scientific, and QIAGEN, the market remains highly competitive at the top tier. These players compete through strong assay menu expansion, integrated diagnostic platforms, digital laboratory solutions, and distribution networks.

Key Industry Developments:

• In May 2026, Integrated DNA Technologies (IDT) announced its entry into the clinical diagnostics market by launching its first in-vitro diagnostic (IVD) next-generation sequencing (NGS) assays, marking a strategic expansion into regulated clinical oncology diagnostics. The new offerings Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx are designed to support molecular pathology laboratories with standardized and clinically validated workflows for cancer testing.
• In January 2025, Revvity Inc. and Element Biosciences announced a strategic collaboration to develop a sequencing-based in-vitro diagnostic (IVD) solution for neonatal testing, aimed at advancing newborn screening through next-generation sequencing (NGS) technology. The partnership focuses on building an integrated, regulatory-grade workflow combining sample preparation, sequencing, and data analysis to enable early detection of genetic and rare diseases in newborns.